Clinical trials: Relatives
Healthy
Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride
to evaluate the bioavailability of ambroxol hydrochloride soft pastilles (test formulation), manufactured by Bolder Arzneimittel GmbH \& Co.
- Trial name
- NCT02572609
- Testing
- Ambroxol hydrochloride soft pastille, Mucosolvan ® adult syrup
- Volunteers
- healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Azithromycin 600 Mg Tablets, Fed
The objective of this randomized, single-dose, two-way crossover evaluation is to compare the relative bioequivalence of a test azithromycin formulation (TEVA Pharmaceuticals USA) to an equivalent oral dose of the commercially…
- Trial name
- NCT00834132
- Testing
- Azithromycin 600 mg Tablet, Zithromax® 600 mg Tablet
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy
Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions
This study was designed to compare the relative bioavailability (rate and extent of absorption) of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets with that of YAZ® Tablets (by Berlex, Inc.) following a single, oral dose (2 x…
- Trial name
- NCT01182207
- Testing
- Drospirenone/Ethinyl Estradiol (Gianvi®), YAZ®
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy
Interaction of BI 691751 With Itraconazole
Investigation of the relative bioavailability of a single dose of BI 691751 when given alone and together with itraconazole; safety and tolerability
- Trial name
- NCT02044393
- Testing
- itraconazole, BI 691751
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Relative Bioavailability Study of Quinine Sulfate Capsules 324mg
The purpose of this study is to evaluate and compare the relative bioavailability of Quinine Sulfate capsules following a single, oral dose in healthy volunteers under fasting and fed conditions.
- Trial name
- NCT00726414
- Testing
- Quinine Sulfate 2 x 324 mg Capsules
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Healthy, Pulmonary Disease, Chronic Obstructive
Relative Bioavailability of of Olodaterol and Ketoconazole
This clinical trial is intended to investigate a possible effect of the p-gp inhibitor ketoconazole on the bioavailability of olodaterol
- Trial name
- NCT01153711
- Testing
- BI 1744, Ketoconazole
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers
This is a phase I, open-label, randomized, 5 period, crossover, single-center trial. The purpose of this trial is to assess the relative bio-availability of L-praziquantel (L-PZQ [MSC2499550A]) oral dispersible tablet (ODT)…
- Trial name
- NCT02271984
- Testing
- MSC2499550A, Cysticide
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Healthy Volunteers
Phase 1, Febuxostat XR Relative Bioavailability Study
This study will assess the relative bioavailability, safety and tolerability following administration of 80 mg single oral doses of 4 febuxostat extended release (XR) formulations.
- Trial name
- NCT02504320
- Testing
- Febuxostat XR 80 mg Capsule F1, Febuxostat XR 80 mg Capsule F2, Febuxostat XR 80 mg Capsule F3
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood
The primary objective of this trial is to investigate the safety and tolerability of BI 1358894 in healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT03210272
- Testing
- BI 1358894, BI 1358894 (Test), BI 1358894 (Reference)
- Where
- Germany
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus
A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects
The purposes of this study are to determine the pharmacokinetics and pharmacodynamics of LY2963016 compared to those of basal insulin.
- Trial name
- NCT01374178
- Testing
- LY2963016, Lantus
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY3202626 in Healthy Participants
The purposes of this study are to determine: If there are any differences in the way LY3202626 is handled by the body when taken in two different forms Whether a high fat meal affects the way the body handles LY3202626 How well…
- Trial name
- NCT03023826
- Testing
- LY3202626 (R-Fasting), LY3202626 (T1-Fasting), LY3202626 (T1-Fed)
- Where
- Singapore
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Uterine Cervical Neoplasms
A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection
Prospective, open-label, within-patient, multi-center study of Lymphoseek in the detection of lymph nodes in subjects with known cancer of the cervix.
- Trial name
- NCT02509585
- Testing
- Tc99m tilmanocept
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Cardinal Health 414, LLC
Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease.
- Conditions
- Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
- Trial name
- NCT01030861
- Testing
- Teplizumab
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 76 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Healthy Volunteers
First in Man Clinical Trial of Emodepside (BAY 44-4400)
This study will investigate the safety, tolerability, and pharmacokinetics of single ascending doses of emodepside (BAY 44-4400) in healthy male volunteers.
- Trial name
- NCT02661178
- Testing
- emodepside (BAY 44-4400)
- Where
- United Kingdom
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Healthy
Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers
This is a Phase I, open label, randomized, crossover trial to investigate the relative bioavailability of tepotinib in healthy volunteers.
- Trial name
- NCT03021642
- Testing
- Tepotinib test (Treatment Period 1), Tepotinib reference (Treatment Period 2), Tepotinib reference (Treatment Period 1)
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Healthy
Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809
To investigate safety, tolerability, and pharmacokinetics of BI 425809 following single rising doses of BI 425809 in healthy male volunteers; To explore dose proportionality of BI 425809 as oral drinking solution; To investigate…
- Trial name
- NCT02068690
- Testing
- BI 425809 PfOS, BI 425809 tablet
- Where
- Germany
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers
Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study
The purpose of this study is to characterize the safety, tolerability and plasma pharmacokinetic (PK) profile of TAK-915 when administered as single and multiple oral suspension doses at escalating dose levels in healthy…
- Trial name
- NCT02461160
- Testing
- TAK-915 suspension, Midazolam, TAK-915 tablet
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting
This study will compare the relative bioavailability (rate and extent of absorption) of 15 mg Mirtazapine (Orally Disintegrating) Tablets manufactured by TEVA Pharmaceutical Industries, Ltd.; distributed by TEVA Pharmaceuticals…
- Trial name
- NCT00834197
- Testing
- Mirtazapine 15 mg (Orally Disintegrating) Tablets, REMERON SolTab® 15 mg Orally Disintegrating Tablets
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA